So the 100th patient enrolled was roughly May 13th[ quote]
The NEUTRALIZE-AKI protocol specifies that an interim analysis will be conducted by the independent DSMB on the primary endpoint of the trial when approximately 50% of patients (100 patients) achieve 90-day follow-up
.
So by August 13th roughly the 100th patient will have completed the 90 day follow up ...then its on to cleaning and checking the data . FDA could ask them to expand the trial ...that would take $